Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome analysis of human postmortem brain tissues in tauopathies, including corticobasal degeneration, progressive supranuclear palsy, and Alzheimer's disease

ABSTRACT: Tauopathies are a group of neurodegenerative diseases characterised by the abnormal accumulation of tau protein within neural and glial cells. The molecular mechanisms of tauopathies remain poorly understood. To identify proteins whose abundance is altered by the disease group, we performed a proteomic analysis of brain homogenate from patients with three tauopathy-related diseases: corticobasal degeneration, progressive supranuclear palsy and Alzheimer's disease.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Takeshi Ikeuchi

PROVIDER: PXD072806 | JPOST Repository | Sat May 09 00:00:00 GMT+01:00 2026

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20241105_TT5600_B-GF-AM-012%231.wiff	Wiff
	20241105_TT5600_B-GF-AM-012%231.wiff.scan	Wiff
	20241105_TT5600_B-GF-AM-012%2310.wiff	Wiff
	20241105_TT5600_B-GF-AM-012%2310.wiff.scan	Wiff
	20241105_TT5600_B-GF-AM-012%2311.wiff	Wiff

Items per page:

1 - 5 of 20

Similar Datasets

Comparative gene expression profiling of Drosophila primary neuronal cultures expressing or not the human Tau0N4RWT protein

Project description:Deciphering the pathophysiological mechanisms that lead from the alteration of human Tau biology to neuronal death in tauopathies including Alzheimer's disease (AD), fronto-temporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pick's disease (PiD), corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) depends notably on the identification of Tau cellular partners and a better understanding of Tau functions. In this aim, we performed gene expression profiling to identify upregulated and downregulated genes in response to ectopic induced expression for 3 days of human Tau0N4RWT protein in Drosophila primary neuronal cultures from Elav-GAL4GS larval brains.

2020-02-11 | E-MTAB-8712 | biostudies-arrayexpress

Molecular features of human pathological Tau distinguish tauopathy-associated dementias (secondary cohort FLEXITau)

Project description:In Alzheimer’s disease (AD), pathological Tau protein shows a progressive accumulation of post-translational modifications (PTMs), reflecting disease severity, progression, and prion-like activity. While many neurodegenerative diseases with dementia display Tau aggregates, the pathological proteoforms of Tau protein from each disease type remain unknown. Here, using quantitative mass spectrometry-based proteomics methods, deep characterization of pathological Tau protein isolated from the brains of 203 human subjects with AD, familial AD (fAD), chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), Pick’s disease (PiD), progressive supranuclear palsy (PSP), dementia with Lewy bodies - symptomatic control (DLB), and healthy controls (CTRL) is performed. Unsupervised data analyses and supervised machine learning identify distinct molecular features of pathological Tau for each disease, enabling molecular disease stratification. This study identifies potential disease-specific biomarkers and therapeutic targets for tauopathies and provides critical pharmacokinetics data for therapeutic and disease mechanism studies.

2026-02-19 | PXD069217 | Pride

Molecular features of human pathological Tau distinguish tauopathy-associated dementias (primary cohort FLEXITau)

2026-02-19 | PXD069437 | Pride

Molecular features of human pathological Tau distinguish tauopathy-associated dementias (primary cohort DDA)

2026-02-19 | PXD069495 | Pride

Molecular features of human pathological Tau distinguish tauopathy-associated dementias (secondary cohort DDA)

2026-02-19 | PXD069249 | Pride

Specific post-translational modifications of the soluble tau protein distinguish between Alzheimer’s disease, 4R-, and 3R-tauopathies

Project description:The tau protein aggregates in several neurodegenerative disorders, referred to as tauopathies. The type of tau isoforms (4R/3R) observed in brain aggregates is used to classify tauopathies. However, distinguishing tauopathies in cerebrospinal fluid remains challenging. Here, we demonstrated that the difference in tau isoforms between tauopathies is only observed in aggregates, not in soluble brain extracts. We therefore used untargeted mass spectrometry to characterize all post-translational modifications of both the aggregated and the soluble tau protein obtained from human brain tissue of patients with Alzheimer’s disease, cortico-basal degeneration, Pick’s disease, and fronto-temporal lobe degeneration. We found specific soluble signatures predictive of each tauopathy and its peculiar type of aggregated tau isoforms. These findings provide potential targets for developing cerebrospinal fluid assays able to distinguish between tauopathies in vivo. The comparison between soluble and aggregated tau features indicates potential mechanisms of tau aggregation, providing novel therapeutic leads for these diseases

2023-06-22 | PXD038901 | Pride

Physiological tau interactome in brain and its link to tauopathies_complete submission

Project description:Alzheimer's disease (AD) and most of other tauopathies are incurable neurodegenerative diseases with unpleasant symptoms and consequences. The common hallmark of all these diseases is tau pathology but its connection with disease progress has not been completely understood so far. Therefore, uncovering novel tau interacting partners and pathology affected molecular pathways can reveal the causes of diseases as well as potential targets for development of AD treatment. Despite of large amount of known tau interacting partners, limited number of studies focused on in vivo tau interactions in disease or healthy conditions are available. Here, we applied an in vivo crosslinking approach, capable of capturing weak and transient protein-protein interactions, to a unique transgenic rat model of progressive tau pathology similar to human AD. We have identified 175 potential novel and known tau interacting proteins by MALDI-TOF mass spectrometry. Several of the most promising candidates for potential drug development were selected for validation by coimmunoprecipitation and colocalization experiments in animal and cellular models.

2020-05-07 | PXD018687 | Pride

RNA-Seq of human primary microglial cells treated with vehicle or human paired helical filaments (PHFs) purified from human tauopathy autopsy brain

Project description:Neuroinflammation is one of the major neuropathological hallmarks of Alzheimer's disease (AD) and related tauopathies. Activated microglia often co-exist in the same brain regions where tau protein accumulates as hyperphosphorylated and aggregated PHFs or neurofibrillary tangles (NFTs) within neurons in patients with AD and related tauopathies. However, the exact mechanisms how pathological tau could induce neuroinflammatory responses are not clear. In this study, we treated primary human microglia with purified human PHFs and performed RNA-sequence analysis.

2021-09-16 | E-MTAB-5742 | biostudies-arrayexpress

Tau posttranslational modifications

Project description:Human tauopathies including Alzheimer's disease are characterized by alterations in the post-translational modification (PTM) pattern of Tau, leading to the formation of insoluble aggregates, neuronal dysfunction and degeneration. We immunoprecipitated Tau from post-mortem brain tissue of early stage Alzheimer's disease patients and age-matched controls, and analyzed PTMs on this soluble pool of Tau protein. In addition to known serine, threonine and tyrosine phosphorylation events, we identified a number of previously unknown monomethylation events on lysines in both control and Alzheimer's patient tissues.

2021-09-09 | PXD017065 | Pride

Tri-snRNP activity modulates tauopathy phenotypes in C. elegans

Project description:Alzheimer's Disease (AD) and other tauopathies are neurodegenerative disorders with devastating consequences for cognition and memory. Pathogenic accumulation of tau can be modeled in Caenorhabditis elegans, which recapitulate human neurodegeneration including aging-dependent accumulation of phosphorylated tau, tau aggregation, neuronal dysfunction, and neuron degeneration. Using forward genetic screens to identify genes modulating tau pathology, we identified a single point mutation in dib-1 that ameliorates tau-driven behavioral defects, prevents neurodegeneration, and decreases tau protein levels. The dib-1 gene encodes a small, highly conserved protein, known as TXNL4A in humans, and participates in mRNA splicing via the U4/U6.U5 tri-snRNP. Notably, heterozygous loss of prp-8, a neighboring protein within the tri-snRNP, also prevents tau-driven neurodegeneration. RNA sequencing of dib-1 mutants demonstrates widespread intron retention consistent with disruption of tri-snRNP functions. Disruption of nonsense-mediated decay further rescues tau-driven phenotypes only in the presence of the dib-1 mutation. TXNL4A levels are decreased in Alzheimer's disease in human frontal cortex, demonstrating the translational relevance of dib-1. Taken together these findings suggest pathological tau impacts splicing function, and spliceosomal activity modulation can ameliorate tauopathy.

2025-10-01 | GSE299236 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data